Corvus Pharmaceuticals, Inc. — 2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019; filed March 9, 2020. Corvus is a clinical-stage oncology company with no product sales or approved products. This is an annual report, not a standalone fourth-quarter filing; quarterly results are summarized below.
Financial performance and position
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $38.0 million | $38.6 million |
| General and administrative expense | $10.9 million | $10.6 million |
| Total operating expenses | $48.9 million | $49.2 million |
| Net loss | $46.7 million | $46.9 million |
| Basic and diluted loss per share | $1.59 | $1.71 |
| Net cash used in operating activities | $37.3 million | $41.0 million |
| Cash, cash equivalents and marketable securities | $78.0 million | $114.6 million |
| Working capital | $69.1 million | $108.6 million |
| Total assets | $83.6 million | $118.2 million |
| Stockholders’ equity | $71.1 million | $110.3 million |
Cash and cash equivalents were $5.2 million at year-end, with $72.8 million in marketable securities. The company reported no borrowings; liabilities included $3.2 million of operating lease liabilities. No operating margin is meaningful because Corvus had no revenue. The company reported an accumulated deficit of $217.1 million.
Quarterly 2019 operating expenses ranged from $11.4 million to $13.6 million, and quarterly net losses ranged from $11.0 million to $13.0 million. Fourth-quarter net loss was $11.0 million, or $0.38 per share.
Material changes versus prior periods
- Net loss was nearly flat year over year, while operating cash use declined by $3.7 million.
- R&D expense fell by $0.6 million. Ciforadenant program costs decreased $4.6 million, primarily due to lower manufacturing costs and enrollment after a protocol amendment; CPI-818 costs increased $1.9 million as clinical activity advanced; CPI-006 costs increased $0.7 million.
- Cash and marketable securities declined $36.6 million. 2019 financing cash flow was negligible, compared with $65.3 million provided by the 2018 follow-on offering.
- In November 2019, Corvus exchanged 1.458 million common shares for pre-funded warrants exercisable at $0.0001 per share. Year-end common shares outstanding were 27.95 million; the warrants had not been exercised.
Business, outlook and principal risks
- Pipeline: Ciforadenant, an adenosine A2A antagonist, was in Phase 2 expansion work, including combination studies with Genentech’s atezolizumab in refractory renal cell cancer and metastatic castration-resistant prostate cancer. CPI-006, an anti-CD73 antibody, and CPI-818, an ITK inhibitor, were in Phase 1/1b trials. CPI-182 and an A2B antagonist remained preclinical.
- Clinical commentary: Management reported preliminary signs of activity and biomarker associations for ciforadenant, including the adenosine gene signature, and early tolerability and immune effects for CPI-006 and CPI-818. These findings are from early-stage trials and are not evidence of established efficacy or approval.
- Funding: Management stated that available resources should fund planned operations for at least 12 months from issuance of the financial statements, but not the completion of development through commercialization. Corvus expects ongoing losses and may need additional financing or collaborations, with potential dilution, debt obligations, or relinquished product rights.
- Execution and safety risks: The candidates remain experimental; trials may fail, be delayed, or reveal serious adverse effects. Combination treatment may increase toxicity. Clinical outcomes, enrollment, manufacturing supply, regulatory decisions, and biomarker validation remain uncertain.
- Other risks: Corvus relies on third parties for clinical trials and manufacturing, has no sales or commercial manufacturing capabilities, and faces competition, reimbursement uncertainty, and intellectual-property risks. Its most important ciforadenant patent protection is licensed, with U.S. composition-of-matter protection expected to expire by July 2029, excluding any extension.
- Contingencies: Potential milestone and royalty payments under licenses, including up to approximately $220 million in aggregate milestones to Vernalis, are contingent and not recorded as balance-sheet liabilities. Corvus reported no material legal proceedings.
- Controls and unusual items: Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not provide an internal-control attestation because of the emerging-growth-company exemption. The exchange warrants and adoption of lease accounting were notable items; adoption of the lease standard resulted in recognition of a right-of-use asset and lease liability.
Most important facts for investors to verify
- Cash runway assumptions and the timing, amount, and terms of any future financing.
- Updated, adequately powered clinical results for ciforadenant, CPI-006, and CPI-818, including durability, safety, and statistical significance.
- Whether the adenosine gene signature or other biomarkers prospectively identify patients likely to benefit.
- Clinical-trial enrollment, timelines, manufacturing capacity, and dependence on third-party suppliers and collaborators.
- Share dilution from options and the 1.458 million pre-funded warrants, along with ownership concentration.
- Current status and scope of licensed and company-owned patent protection, contingent milestones, and royalty obligations.